HAQ group, n (%) | 643 (59) | 328 (30) | 115 (11) | 590 (58) | 312 (31) | 108 (11) | 657 (65) | 254 (25) | 99 (10) |
Female, n (%) | 388 (60) | 234 (71) | 83 (72) | 361 (61) | 226 (72) | 78 (72) | 404 (61) | 184 (72) | 77 (78) |
Median (IQR) age at onset (years) | 51 (39–62) | 55 (43–69) | 65 (53–74) | 52 (39–62) | 56 (43.5–69) | 65 (52.5–73) | 53 (40–63) | 55 (44–69) | 66 (51–73) |
Median (IQR) swollen and tender joint count | 1 (0–5) | 6 (2–11.5) | 11 (4–19) | 2 (0-5) | 6 (2–12) | 10.5 (4–18.5) | 0 (0–2) | 2 (0–7) | 4 (2–12) |
RF titre ⩾1:40 at baseline, n (%) | 149 (23) | 78 (24) | 39 (34) | 136 (23) | 77 (25) | 35 (32) | 154 (23) | 61 (24) | 33 (33) |
RF titre ⩾1:80 at baseline, n (%) | 117 (18) | 67 (20) | 33 (29) | 108 (18) | 66 (21) | 30 (28) | 124 (19) | 52 (20) | 28 (28) |
Satisfy ACR criteria at baseline, n (%) | 203 (32) | 196 (60) | 92 (80) | 189 (32) | 189 (61) | 86 (80) | 243 (37) | 146 (57) | 75 (76) |
Mean (95% CI) DAS28 score | 3.36 (3.3 to 3.5) | 4.71 (4.6 to 4.8) | 5.55 (5.4 to 5.8) | 3.38 (3.3 to 3.5) | 4.72 (4.6 to 4.9) | 5.53 (5.3 to 5.7) | 3.63 (3.5 to 3.7) | 4.54 (4.4 to 4.7) | 5.27 (5.04 to 5.5) |
Treated with DMARDs by first year, n (%) | 208 (32) | 187 (57) | 79 (69) | 201 (34) | 185 (59) | 77 (71) | 254 (39) | 135 (53) | 74 (75) |
All-cause mortality per 1000 pyr over 10 years | 12.1 | 23.5 | 39.7 | 11.5 | 22.1 | 35.8 | 11.9 | 23.1 | 38.9 |
CVD mortality per 1000 pyr over 10 years | 7 | 12.6 | 23.3 | 6.7 | 11.3 | 20.6 | 6.4 | 13.4 | 21.3 |